Krystal Biotech’s (KRYS) Buy Rating Reiterated at Chardan Capital

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “buy” rating reissued by Chardan Capital in a report released on Wednesday,Benzinga reports. They presently have a $219.00 target price on the stock. Chardan Capital’s price target would indicate a potential upside of 57.02% from the stock’s current price.

A number of other equities research analysts have also weighed in on KRYS. HC Wainwright restated a “buy” rating and issued a $240.00 target price on shares of Krystal Biotech in a report on Tuesday. Citigroup lifted their target price on Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research report on Thursday, February 20th. Jefferies Financial Group began coverage on shares of Krystal Biotech in a report on Wednesday, March 5th. They set a “buy” rating and a $245.00 price target on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 target price on shares of Krystal Biotech in a report on Thursday, February 20th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $222.86.

Krystal Biotech Stock Performance

Shares of NASDAQ:KRYS opened at $139.47 on Wednesday. The firm has a market cap of $4.03 billion, a P/E ratio of 46.65 and a beta of 0.79. Krystal Biotech has a 52-week low of $135.00 and a 52-week high of $219.34. The business’s 50 day simple moving average is $173.96 and its two-hundred day simple moving average is $170.88.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.38 by ($0.18). Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business had revenue of $88.18 million during the quarter, compared to analyst estimates of $98.66 million. On average, equities analysts forecast that Krystal Biotech will post 6.14 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the sale, the insider now directly owns 1,463,711 shares of the company’s stock, valued at $260,233,178.69. This trade represents a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CAO Kathryn Romano sold 750 shares of the company’s stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at $2,208,472.88. This represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. 13.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Krystal Biotech

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Fifth Third Bancorp lifted its stake in shares of Krystal Biotech by 159.1% during the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company’s stock valued at $31,000 after buying an additional 105 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of Krystal Biotech during the third quarter worth $40,000. GF Fund Management CO. LTD. purchased a new position in shares of Krystal Biotech in the fourth quarter valued at $95,000. GAMMA Investing LLC grew its position in shares of Krystal Biotech by 179.3% in the first quarter. GAMMA Investing LLC now owns 673 shares of the company’s stock valued at $121,000 after purchasing an additional 432 shares in the last quarter. Finally, Covestor Ltd raised its stake in shares of Krystal Biotech by 972.7% during the 4th quarter. Covestor Ltd now owns 708 shares of the company’s stock valued at $111,000 after purchasing an additional 642 shares during the period. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).